Why is the screening rate in lung cancer still low? A seven-country analysis of the factors affecting adoption
Frontiers in Public Health · 09.11.2023 · 11
DOI: 10.3389/fpubh.2023.1264342 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Public Health, online erschienen am 09.11.2023. Verfasst von Charlotte Poon und 4 weiteren Autor:innen. Beteiligte Einrichtung: Charles River Associates, London, United Kingdom. Hauptthemen laut MEDLINE: Lung Neoplasms. Die Arbeit wurde bisher 51-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Strong evidence of lung cancer screening’s effectiveness in mortality reduction, as demonstrated in the National Lung Screening Trial (NLST) in the US and the Dutch–Belgian Randomized Lung Cancer Screening Trial (NELSON), has prompted countries to implement formal lung cancer screening programs. However, adoption rates remain largely low. This study aims to understand how lung cancer screening programs are currently performing. It also identifies the barriers and enablers contributing to adoption of lung cancer screening across 10 case study countries: Canada, China, Croatia, Japan, Poland, South Korea and the United States. Adoption rates vary significantly across studied countries. We find five main factors impacting adoption: (1) political prioritization of lung cancer (2) financial incentives/cost sharing and hidden ancillary costs (3) infrastructure to support provision of screening services (4) awareness around lung cancer screening and risk factors and (5) cultural views and stigma around lung cancer. Although these factors have application across the countries, the weighting of each factor on driving or hindering adoption varies by country. The five areas set out by this research should be factored into policy making and implementation to maximize effectiveness and outreach of lung cancer screening programs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Charles River Associates, London, United Kingdom.
- MSD International Business GmbH, Kriens, Switzerland.
- Merck & Co., Inc., Kenilworth, NJ, United States.
Zitieren
APA
Poon, C., Wilsdon, T., Sarwar, I., Roediger, A., & Yuan, M. (2023). Why is the screening rate in lung cancer still low? A seven-country analysis of the factors affecting adoption. Frontiers in Public Health, 11. https://doi.org/10.3389/fpubh.2023.1264342
Vancouver
Poon C, Wilsdon T, Sarwar I, Roediger A, Yuan M. Why is the screening rate in lung cancer still low? A seven-country analysis of the factors affecting adoption. Frontiers in Public Health. 2023;11. doi:10.3389/fpubh.2023.1264342
BibTeX
@article{Poon2023,
author = {Poon, Charlotte and Wilsdon, Tim and Sarwar, Iqra and Roediger, Alexander and Yuan, Megan},
title = {Why is the screening rate in lung cancer still low? A seven-country analysis of the factors affecting adoption},
journal = {Frontiers in Public Health},
year = {2023},
volume = {11},
doi = {10.3389/fpubh.2023.1264342}
}
EUVIMED